1. Medtech Insight
  2. >>Archive

People In Brief

The latest moves by movers and shakers in the medical device and diagnostics industries.

Orthopedic device firm says President, CEO and Chairman Stephen P. MacMillan is resigning for family reasons, effective Feb. 8. MacMillan joined Stryker in 2003 as president and chief operating officer, and became CEO in January 2005. (See Also see "Bear Stearns Healthcare Conference In Brief" - Medtech Insight, 27 September, 2004..) The company has named Curt Hartman, VP and chief financial officer, as interim CEO and William U. Parfet, lead independent director, as non-executive chairman while the board searches for a permanent successor to MacMillan, considering both internal and external candidates.

In March 2011, MacMillan was named AdvaMed chair-elect for 2012-2013 and was slated to take over that post in March,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

US FDA Unveils Plans To Consolidate Support Services

 
• By Derrick Gingery and Sue Sutter

Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.

A Year After Exiting The Ventilator Market, Medtronic Recalls Thousands Of Newport Devices

 
• By Brian Bossetta

After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.

‘UK Must Put Adoption On A Par With Innovation’

 
• By Ashley Yeo

Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.